Topic “a12”
This topics current hotness is 0 - That means that it was covered by 0 articles per day over the last week.
Since 2008-08-30, this topic was covered by 4 Articles from 3 Feeds.
FeedItems
2008-09-29
-
Randomized Phase 2 Study of IMC-A12 for Advanced Breast Cancer Commences Patient Enrollment
ImClone Systems Incorporated , a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed randomized Phase 2 clinical trial of ... read
2008-09-27
-
Randomized Phase 2 Study Of IMC-A12 For Advanced Breast Cancer Commences Patient Enrollment
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12, ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in women with advanced breast cancer has commenced patient enrollment. read
2008-09-10
-
Bigger road demanded not for cars but for a yacht!
Seeing a massive yacht on a busy road could have been a sight I would have loved to enjoy in person. But I do pity the drivers who must have pulled their hair and clawed their eyes out of frustration considering the bumper to bumper situation. This slow boat caused lengthy tailbacks on the A12 as it made its way from the East of England to the annual Southampton Boat Show, which starts at the end of this week.... read
2008-08-30
-
Randomized Phase 2 Study Of IMC-A12 And IMC-1121B For Advanced Prostate Cancer Commences Patient Enrollment
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed Phase 2 clinical trial in patients with advanced prostate cancer randomized to treatment with either IMC-A12 or IMC-1121B plus mitoxantrone and prednisone has commenced patient enrollment. read